Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

February 15, 2027

Study Completion Date

June 1, 2027

Conditions

Glioblastoma

Interventions

DRUG

IDO1 Inhibitor BMS-986205 25mg

Given PO

DRUG

Nivolumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Temozolomide

Given PO

DRUG

IDO1 Inhibitor BMS-986205 50 mg

Given PO

DRUG

IDO1 Inhibitor BMS-986205 100 mg

Given PO

Trial Locations (1)

Northwestern University, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER